Osteoprotegerin and kidney disease

Journal of Nephrology

Volumn 27, Issue 6, 2014, Pages 607-617

  Montañez Barragán, Alejandra ^a   Gómez Barrera, Isaias ^a   Sanchez Niño, Maria D ^b,d   Ucero, Alvaro C ^c,d   González Espinoza, Liliana ^c,d   Ortiz, Alberto ^c,d,e  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c Section of Nephrology   (Spain)

^d REDINREN   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Exosome; Kidney; Mortality; Osteoprotegerin; TRAIL; Vascular calcification

Indexed keywords

ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LYMPHOTOXIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITAMIN D; RECOMBINANT PROTEIN;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; DIALYSIS; DOWN REGULATION; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEPHROTIC SYNDROME; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; COMPLICATION; KIDNEY DISEASES; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; HUMANS; KIDNEY DISEASES; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR CALCIFICATION;

EID: 84911999199     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0092-x     Document Type: Review

References (104)

1. Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382(9888):260
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339
3. de Jager DJ, Grootendorst DC, Jager KJ et al (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302(16):1782
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl 113:S1
5. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A (2012) Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol 21(5):372
6. Jamal SA, Vandermeer B, Raggi P et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268
7. Ortiz A, Sanchez-Niño MD (2013) The demise of calcium-based phosphate binders. Lancet 382(9900):1232
8. Izquierdo MC, Perez-Gomez MV, Sanchez-Niño MD et al (2012) Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant 27(Suppl 4):iv6
9. Hu MC, Shi M, Zhang J et al (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22(1):124
10. Salamat M, Dhar PK, Neagu DL, Lyon JB (2010) Aortic calcification in a patient with Hutchinson–Gilford progeria syndrome. Pediatr Cardiol 31(6):925
11. Massy ZA, Drüeke TB (2013) Vascular calcification. Curr Opin Nephrol Hypertens 22(4):405
12. Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24(2):179
13. de Francisco ALM, Rodríguez M (2013) Magnesium—its role in CKD. Nefrologia 33(3):389
14. Martin TJ (2013) Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop 4(4):186
15. Gallagher JC, Tella SH (2013) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2013.09.008
16. Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12(9):1260
17. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745
18. Pennica D, Nedwin GE, Hayflick JS et al (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312(5996):724
19. Armitage RJ (1994) Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6(3):407
20. Cosman D (1994) A family of ligands for the TNF receptor superfamily. Stem Cells 12(5):440
21. Lotz M, Setareh M, von Kempis J, Schwarz H (1996) The nerve growth factor/tumor necrosis factor receptor family. J Leukoc Biol 60(1):1
22. Schneeweis LA, Willard D, Milla ME (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280(50):41155
23. Rashtchizadeh N, Ghorbanihaghjo A, Argani H et al (2012) Serum receptor activator of nuclear factor-κ B ligand, osteoprotegrin, and intact parathyroid hormone in hemodialysis and renal transplant patients. Ther Apher Dial 16(6):600
24. Sato T, Tominaga Y, Iwasaki Y et al (2001) Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 38(4 Suppl 1):S175
25. Silva I, Branco JC (2011) Rank/Rankl/opg: literature review. Acta Reumatol Port 36(3):209
26. Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J (2009) New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 58(1):29
27. Papadopouli AE, Klonaris CN, Theocharis SE (2008) Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol 23(4):497
28. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15(1):2
29. Klejna K, Naumnik B, Gasowska K, Myśliwiec M (2009) OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 47(2):199
30. Wright HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2(1):56
31. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309
32. Gordin D, Soro-Paavonen A, Thomas MC et al (2013) Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care 36(7):1827
33. Vitovski S, Phillips JS, Sayers J, Croucher PI (2007) Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282(43):31601
34. Lamoureux F, Picarda G, Garrigue-Antar L et al (2009) Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res 69(2):526
35. Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20(11):1971
36. Boyce BF, Xing L (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9(Suppl 1):S1
37. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139
38. Li Y, Toraldo G, Li A et al (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109(9):3839
39. Romas E (2009) Clinical applications of RANK-ligand inhibition. Intern Med J 39(2):110
40. Emery JG, McDonnell P, Burke MB et al (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273(23):14363
41. Lorz C, Benito-Martín A, Boucherot A et al (2008) The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 19(5):904
42. Sanchez-Niño MD, Benito-Martin A, Gonçalves S et al (2010) TNF superfamily: a growing saga of kidney injury modulators. Mediat Inflamm 2010. doi:10.1155/2010/182958
43. Lorz C, Benito A, Ucero AC, Santamaría B, Ortiz A (2009) Trail and kidney disease. Front Biosci (Landmark Ed) 14:3740
44. Pritzker LB, Scatena M, Giachelli CM (2004) The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15(6):2834
45. Zauli G, Corallini F, Bossi F et al (2007) Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110(2):536
46. Kobayashi-Sakamoto M, Isogai E, Holen I (2010) Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol 85(1):26
47. Benslimane-Ahmim Z, Poirier F, Delomenie C et al (2013) Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis 16(3):575
48. Lawrie A, Waterman E, Southwood M et al (2008) Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 172(1):256
49. Bennett BJ, Scatena M, Kirk EA et al (2006) Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arterioscler Thromb Vasc Biol 26(9):2117
50. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188(5):997
51. Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4):463
52. Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95(11):1046
53. Wu Y, Liu J, Guo H et al (2013) Establishment of OPG transgenic mice and the effect of OPG on bone microarchitecture. Int J Endocrinol 2013:125932
54. Malan E (1975) 23rd Congress of the European Society of Cardiovascular Surgery. J Cardiovasc Surg (Torino) 16(3):215
55. http://omim.org/entry/602643. Accessed 1 Jan 2014
56. Rehman T, Ali R, Taylor C, Yonas H (2010) Bilateral giant cavernous carotid artery aneurysms in a child with juvenile Paget’s disease. World Neurosurg 73(6):691
57. Allen CA, Hart BL, Taylor CL, Clericuzio CL (2008) Bilateral cavernous internal carotid aneurysms in a child with juvenile paget disease and osteoprotegerin deficiency. Am J Neuroradiol 29(1):7
58. Saratzis A, Sarafidis P, Melas N, Saratzis N, Kitas G (2013) Impaired renal function is associated with mortality and morbidity after endovascular abdominal aortic aneurysm repair. J Vasc Surg 58(4):879
59. Patel VI, Lancaster RT, Mukhopadhyay S et al (2012) Impact of chronic kidney disease on outcomes after abdominal aortic aneurysm repair. J Vasc Surg 56(5):1206
60. Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401
61. Secchiero P, Zauli G (2008) Letter by Secchiero and Zauli regarding article, “osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice”. Circulation 118(2):e18 (author reply e19)
62. Morony S, Tintut Y, Zhang Z et al (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation 117(3):411
63. Toffoli B, Bernardi S, Candido R et al (2011) Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 331(1):136
64. Corallini F, Rimondi E, Secchiero P (2008) TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 13:135
65. Toffoli B, Pickering RJ, Tsorotes D et al (2011) Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis 218(1):61
66. Price PA, June HH, Buckley JR, Williamson MK (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21(10):1610
67. Hayashi M, Takamatsu I, Kanno Y et al (2012) A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27(4):1580
68. Body JJ, Greipp P, Coleman RE et al (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl):887
69. Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9(Suppl 1):S7
70. Kohli SS, Kohli VS (2011) Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab 15(3):175
71. http://www.ema.europa.eu/. Accessed 1 Jan 2014
72. http://clinicaltrials.gov/. Accessed 1 Jan 2014
73. Ortiz A, Massy ZA, Fliser D et al (2012) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 8(3):141
74. Kiechl S, Schett G, Wenning G et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175
75. Mikami S, Hamano T, Fujii N et al (2008) Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res 31(6):1163
76. Jiang JQ, Lin S, Xu PC, Zheng ZF, Jia JY (2011) Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease–mineral and bone disorder. Nephrology (Carlton) 16(6):588
77. Morena M, Dupuy AM, Jaussent I et al (2009) A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 24(11):3389
78. Morena M, Jaussent I, Halkovich A et al (2012) Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One 7(5):e36175
79. Scialla JJ, Leonard MB, Townsend RR et al (2011) Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 6(11):2612
80. Sigrist MK, Levin A, Er L, McIntyre CW (2009) Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 24(10):3157
81. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG (2012) FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease–mineral bone disorder and the heart. Nephrol Dial Transplant 27(2):727
82. Duranton F, Cohen G, De Smet R et al (2012) Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23(7):1258
83. Mohamed GB, Abdel-Latif EA (2011) Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. Saudi J Kidney Dis Transplant 22(5):955
84. Liabeuf S, Okazaki H, Desjardins L et al (2013) Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant [Epub ahead of print]
85. Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA et al (2012) Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest 42(5):548
86. Shin JY, Shin YG, Chung CH (2006) Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 29(7):1664
87. Coen G, Ballanti P, Balducci A et al (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17(2):233
88. Janda K, Krzanowski M, Chowaniec E et al (2013) Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn 123(4):149
89. Lederle FA (2012) The strange relationship between diabetes and abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 43(3):254
90. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2006) Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154(1):75
91. Pencak P, Czerwieńska B, Ficek R et al (2013) Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol 14:10
92. Bargnoux AS, Dupuy AM, Garrigue V et al (2009) Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. Am J Transplant 9(11):2571
93. Hjelmesaeth J, Ueland T, Flyvbjerg A et al (2006) Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 17(6):1746
94. Matsubara K, Stenvinkel P, Qureshi AR et al (2009) Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 22(6):774
95. Svensson M, Dahle DO, Mjøen G et al (2012) Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant 27(6):2571
96. Meneghini M, Regalia A, Alfieri C et al (2013) Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation 96(1):42
97. Lewis JR, Lim WH, Zhu K et al (2014) Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study. Am J Nephrol 39(1):66
98. Zhou S, Fang X, Xin H, Li W, Qiu H, Guan S (2013) Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway. PLoS One 8(7):e68987
99. Fernández Fernández B, Elewa U, Sánchez-Niño MD et al (2012) 2012 Update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med 103(4):219
100. Szteyn S (1988) Types of neurons in nucleus olivaris inferior of the European bison. J Hirnforsch 29(3):353
101. Benito-Martin A, Ucero AC, Zubiri I et al (2013) Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. PLoS One 8(8):e72387
102. Kiani AN, Johnson K, Chen C et al (2009) Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 36(10):2224
103. West SL, Lok CE, Jamal SA (2013) Osteoprotegerin and fractures in men and women with chronic kidney disease. J Bone Miner Metab. doi:10.1007/s00774-013-0506-1
104. Luan X, Lu Q, Jiang Y et al (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 189(1):245